ИММУНОГЕННЫЕ КОМПОЗИЦИИ НА ОСНОВЕ CHLAMYDIA TRACHOMATIS

1. Белок, состоящий из аминокислотной последовательности SEQ ID NO: 46, отличающийся тем, что указанная аминокислотная последовательность содержит одну или несколько мутаций, где указанные одна или несколько мутаций присутствуют в положении(ях) аминокислотного(ых) остатка(ов), выбранного(ых) из группы, состоящей из остатков 64, 126, 157, 162, 179, 207, 217, 220, 275 и 420. ! 2. Белок по п.1, где указанной мутацией независимо является замена, инсерция или делеция, предпочтительно, одна или несколько мутаций, перечисленных в таблице 7. ! 3. Белок по п.1 или 2, где указанные одна или несколько мутаций изменяют иммуногенность белка. ! 4. Белок по п.1 или 2, где указанный белок содержит одну или несколько мутированных последовательностей, выбранных из группы последовательностей, состоящих из SEQ ID No: 1, 4, 6, 8, 11, 12, 13, 16, 18, 19, 20, 21, 23 и/или 27. ! 5. Белок по п.4, содержащий последовательность SEQ ID No: 11, 4 или 6. ! 6. Белок по п.4, содержащий последовательность SEQ ID No: 13 или 8. ! 7. Белок по п.4, содержащий последовательность SEQ ID No: 12 или 1. ! 8. Белок по п.2, имеющий мутацию в положении аминокислотного остатка 64 и/или 162. ! 9. Белок по п.4, содержащий последовательности SEQ ID No: 16, 18, 19, 20, 21, 22, 23 или 27. ! 10. Белок, содержащий аминокислотную последовательность белка по любому из предшествующих пунктов или один или несколько фрагментов, состоящих по меньшей мере из 7 смежных аминокислот белка по любому из предшествующих пунктов. ! 11. Белок по п.10, где один или несколько фрагментов содержат одну или несколько мутаций, присутствующих в положении(ях) аминокислотного(ых) остатка(ов), выбранного(ых) из группы, состоящей из остатков 64, 126, 157, 162, 179, 207, 217, 220, 275 и/или 420. ! 12. Антитело, которое связывается с белком по лю� РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2007 146 137 (13) A (51) МПК C07K 14/295 (2006.01) A61K 39/118 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ЗАЯВКА НА ...

Вакцины против Chlamydia sp.

Extraktionsverfahren.

CHLAMYIDIA TRACHOMATIS SPECIFIC ONES PEPTIDEN AND THEIR APPLICATION IN THE PROOF PROCEDURE

CHLAMYDIA ANTIGENS, APPROPRIATE DNS OF FRAGMENTS AND YOUR USES

CHLAMYDIA ANTIGENS AND APPROPRIATE DNA OF FRAGMENTS AND THEIR USES

CHLAMYDIA ANTIGENS AND THEIR CORRESPONDING DNA OF FRAGMENTS AND USES OF IT

TWO-STEP PROCEDURE FOR THE INOCULATION APPROXIMATELY CHLAMYDIA

EXTRACTION PROCEDURE

Compositions for and methods of identifying antigens

Chlamydia antigens and corresponding dna fragments and uses thereof

Chlamydial peptides and their mimics in demyelinating disease

Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Two-step immunization procedure against chlamydia infection

Methods and compositions for preventing or retarding the development of atherosclerotic lesions

Dna immunization against (chlamydia) infection

Chlamydia pneumoniae genome sequence

Chlamydia antigens and corresponding DNA fragments and uses thereof

Two-step immunization procedure against (chlamydia) infection

Antigenic polypeptide of chlamydia pneumoniae

Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding an omp P6 precursor of a strain of Chlamydia pneumoniae and a promoter to effect expression of the omp P6 precursor in the host. Modifications are possible within the scope of this invention.

MEDICAMENT

... ▓▓▓The present invention concerns treatment, prevention and diagnosis of ▓infection due to Chlamydia pneumoniae and in particular to the ▓prevention and treatment of atherosclerosis, including coronary ▓atherosclerosis, caused by same.▓ ...

TWO-STEP IMMUNIZATION PROCEDURE AGAINST CHLAMYDIA INFECTION

A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infectio n by a strain of Chlamydia specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding OMP (outer membrane protein) of a strain ofChlamydia pneumoniae and a promoter to effect expression of the OMP (outer membrane protein) gene in the host. Modifications are possible within the scope of this invention.

IMMUNIZATION AGAINST CHLAMYDIA INFECTION

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a Mgp002 polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. Truncated forms of the full-length Mgp002 gene are useful immunogens for protecting against disease caused by infection with Chlamydia. The invention further provides recombinant Mgp002 protein useful for protecting against disease caused by infection with Chlamydia.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia pneumoniae operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from C. pneumoniae and are selected from an ATP-binding cassette protein, a secretory locus ORF, an endopeptidase, a protease, a metalloprotease, CLP protease ATPase, a CLP protease subunit, a translycolase/transpeptidase, a CLPc protease and thioredoxin.

NOVEL DIAGNOSTIC AGENTS OF CHRONIC OR PERSISTENT CHLAMYDIAL DISEASES AND USES THEREOF

The present invention discloses compositions and methods for detecting organisms of the Chlamydiaceae family, including species of Chlamydia and Chlamydophila, in the persistent phase of their developmental cycle and for the diagnosis of chronic or persistent infections caused by such organisms. The present invention also discloses methods for screening agents that are useful inter alia for modulating a gene whose expression is altered in the persistent phase of the chlamydial developmental cycle or for modulating the level and/or functional activity of an expression product of that gene. Also disclosed are methods and compositions for the treatment and/or prophylaxis of infections, including chronic infections, caused by chamydial organisms using the aforesaid modulatory agents and optionally agents that are effective in modulating the expression of a gene associated with the lytic phase of said developmental cycle or in modulating the level and/or functional activity of an expression ...

TRANSLOCATOR COMPONENT DERIVATIVES AND USES THEREOF

The present invention relates to a novel tool in the inhibition or modulatio n of the type III secretion system of bacteria. More particularly, the inventi on relates to molecules, such as a modified translocator component molecule, that affect o r inhibit said secretion system and their use in compositions and methods for the treatment or prevention of a disease caused by a bacterium having such a type III secretion system.

CHLAMYDIA ANTIGENS

Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.

IMMUNOGENS FOR STIMULATING MUCOSAL IMMUNITY

This patent application relates to immunogens for stimulating mucosal immunity to a pathogen capable of infecting its host through contact with mammalian mucosal membranes. In particular, this invention discloses a number of polypeptides and genetic constructs that include a membrane binding polypeptide operably linked to a peptide from a pathogen. Methods are detailed throughout the claims and the specification for introducing these immunogens into a mammal to stimulate mucosal immune responses.

ВАКЦИНЫ ПРОТИВ ХЛАМИДИОЗА

Настоящее изобретение относится к композициям, содержащим белки или полинуклеотиды Chlamydia sp., в частности комбинации белков или кодирующих их полинуклеотидов, и к способам применения данных белков или полинуклеотидов в лечении, предупреждении или диагностике хламидиоза.

ВАКЦИНА ПРОТИВ ИНФЕКЦИИ CHLAMYDIA

Заявленное изобретение относится к композиции, содержащей комбинацию белка Chlamydia Ct-858 или его иммуногенного фрагмента, или полинуклеотида или полинуклеотида, кодирующего их, и по меньшей мере одного дополнительного белка Chlamydia или его иммуногенного фрагмента, или полинуклеотида, кодирующего их, выбранного из Swib, Momp, Ct-875, Ct-622, Ct-089, домена-пассажира Pmpg и домена-пассажира Pmpd, и к способам применения таких белков или полинуклеотидов в лечении, предупреждении или диагностике инфекции Chlamydia.

CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION

METHOD FOR DELIVERY OF SUBSTANCES TO INTRACELLULAR MICROORGANISMS

The present invention concerns a method of delivering substances to obligate intracellular microorganisms. Further, the invention concerns a method of treatment of infections of intracellular microorganisms. Further, the invention concerns substances suitable for treatment of infections of intracellular microorganisms. In addition, the invention concerns stable transformants of obligate intracellular microorganisms.

i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of i(Chlamydia trachomatis), such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the i(Chlamydia trachomatis) genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing i(Chlamydia trachomatis) infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences ...

COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER

This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

La présente invention concerne une méthode d'immunisation d'un organisme hôte, tel qu'un humain, par un acide nucléique, notamment l'ADN, contre des maladies provoquées par une infection due à une souche Chlamydia, spécifiquement C. pneumoniae, en utilisant un vecteur contenant une séquence nucléotidique codant une protéine de 60 kDa riche en cystéine de souche Chlamydia pneumoniae, et un promoteur pour effectuer l'expression du gène de la protéine membranaire de 60 kD riche en cystéine chez l'organisme hôte. Des modifications sont possibles dans le champ de l'invention.

PNA PROBES FOR DETECTION OF NEISSERIA GONORRHOEAE AND CHLAMYDIA TRACHOMATIS

Specific peptide nucleic acid (PNA) probes for detecting a sexual transmitted disease caused by Neisseria gonorrhoeae or Chlamydia trachomatis comprising N-(2-aminoethyl)glycine units in amide linkage with the glycine nitrogen connected to naturally occurring nucleobases or non-naturally occurring nucleobases by a methylene carbonyl linker and said probes capable of hybridizing to 16S or 23S rRNA or rDNA of Neisseria gonorrhoeae or Chlamydia trachomatis are described. PNA is a very stable molecule with very high affinity for nucleic acid allowing a PNA probe to be shorter than conventional nucleic acid probes.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

La présente invention concerne une méthode d'immunisation d'un hôte par acide nucléique (y compris l'ADN), notamment des sujets humains contre une maladie provoquée par une infection due à une souche de Chlamydia, spécifiquement C. pneumoniae, utilisant un vecteur contenant une séquence nucléotidique codant une ATP/ADP translocase d'une souche de Chlamydia pneumoniae ainsi qu'un promoteur pour provoquer l'expression du gène d'ATP/ADP translocase chez l'hôte. Des modifications sont possibles dans la portée de cette invention.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

Succinctement, cette invention concerne une technique d'immunisation par acide nucléique (dont l'ADN) d'un hôte, homme y compris, contre des maladies dues à une infection par une souche de Chlamydia, plus particulièrement de C. pneumoniae. Cette technique fait intervenir un vecteur qui renferme une séquence nucléotidique codant pour une protéine de membrane externe de 98 kDa d'une souche de Chlamydia pneumoniae et un promoteur pour permettre l'expression d'un gène de la protéine de membrane extérieure de 98kDa chez l'hôte. Certaines modifications sont possibles dans le cadre de cette invention.

IMMUNIZATION AGAINST CHLAMYDIA INFECTION

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from the Chalmydiagene 60kCRMP gene including truncated forms of the gene. The invention further provides recombinant 60kCRMP protein useful for protecting against disease caused by infection with Chlamydia.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Chlamydia protein, gene sequence and uses thereof

A high molecular weight ("HMW") protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.

Nucleotide deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins

The present invention relates to novel polypeptides comprising a unique "chlamydial-specific" primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.

DNA immunization against chlamydia infection

Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically acceptable carrier for in vivo administration to the host.

Chlamydia antigens and corresponding DNA fragments and uses thereof

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.

MEDICAMENT FOR THE TREATMENT OF C. PNEUMONIAE INFECTIONS

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

CHLAMYDIA 98KD PUTATIVE OUTER MEMBRANE PROTEIN AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically i(C. pneumoniae), employing a vector, containing a nucleotide sequence encoding a 98 kDa putative outer membrane protein of a strain of i(Chlamydia pneumoniae) and a promoter to effect expression of the i(98 kDa putative outer membrane protein) gene in the host. Modifications are possible within the scope of this invention.

АНТИГЕНЫ ХЛАМИДИИ

1. Белок, содержащий любую аминокислотную последовательность из SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 136 или SEQ ID NO: 140, для использования в терапии или диагностике.2. Белок, имеющий 50% или более идентичности последовательности с белком по п.1.3. Белок, содержащий фрагмент аминокислотной последовательности по п.1 или 2.4. Белок по п.3, в котором фрагмент содержит по меньшей мере 8 последовательных аминокислот из аминокислотной последовательности по п.1 или 2.5. Антитело, связывающееся с белком по любому из пп.1-4, для применения в терапии или диагностике.6. Молекула нуклеиновой кислоты, кодирующая белок или антитело по любому из пп.1-5, для применения в терапии или диагностике.7. Молекула нуклеиновой кислоты по п.6, содержащая любую нуклеотидную последовательность из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.8. Молекула нуклеиновой кислоты, содержащая фрагмент любой нуклеотидной последовательности из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 или SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.9. Молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, комплементарную молекуле нуклеиновой кислоты по любому из пп.6-8.10. Молекула нуклеиновой кислоты, содержащая нуклеотидные последовательности, имеющие 50% или более идентичности последовательности с молекулой нуклеиновой кислоты по любому из пп.6-9. ...

CHLAMYDIA-IMPFSTOFFE UND IMMUNOGENE CHLAMYDIA-ZUSAMMENSETZUNGEN, DIE EIN ANTIGEN DER ÄUSSEREN MEMBRAN ENTHALTEN, SOWIE VERFAHREN ZU DEREN HERSTELLUNG

MODIFIABLE DETERGENT COMPOUNDS AND THEIR USE IN ASSAYS

A method for temporarily increasing the hydrophilic properties of a material, such as a microbial antigen or antibody thereto, comprises contacting the material with a detergent compound containing a modifiable group and subsequently modifying said group (e.g. by cleavage, oxidation or reduction) by addition of a suitable reagent so as to decrease or destroy the detergent properties of said compound. The method may be used to prepare an analyte for assay, subsequent removal of the detergent being made more efficient or even eliminated by means of the modifying reagent. Detergent compounds of general formula CH3(CH2)n-A- (CH2)mOW (or their salts) where A is -S- or -S-CH=CH-; W is H or SO3H; and n is 2-4 and m is 6-11 when A is -S- or n and m are each 1-10 when A is -S-CH=CH- are also claimed.

Antigens

PRESUMED 98 KD PROTEIN OUTER DIAPHRAGM OF CHLAMYDIA AND BUT CODING DNS AS WELL AS THEIR USE

EXTERIOR MEMBRANPOLYPEPTID OF CHLAMYDIA PNEUMONIAE AS WELL AS FRAGMENTS OF IT AND THEIR USE, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF AN INFECTION

PROOF OF A WITH BREATHING DISEASES CONNECTIONS OF SINGLE TRUNK OF CHLAMYDIA.

CHLAMYDIA VACCINES

IMMUNOGEN LHRH PEPTIDKONSTRUKION AND SYNTHETIC, UNIVERSAL ONE IMMUNSTIMULATOREN AS VACCINES

REKOMBINANT PGP3, PROCEDURE FOR ITS PRODUCTION, AND ITS USE IN THE DIAGNOSIS AND THERAPY

Recombinant pgp3, methods of preparation and use in diagnosis and therapy

Compounds for detection of infection by chlamydophila abortus

Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines

Medicament

Chlamydia antigens and corresponding DNA fragments and uses thereof

(chlamydia) antigens and corresponding dna fragments and uses thereof

Novel surface exposed proteins from chlamydia pneumoniae

Novel diagnostic agents and uses therefor

Chlamydia antigens and uses thereof

The present invention relates generally to ...

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

The present invention provides purified and isolated plynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100686 RY 54 (SEQ ID Nos: 1 and 14), CPN100696 RY-55 (SEQ ID Nos: 2 and 15), CPN100709 RY-57 (SEQ ID Nos: 3 and 16), CPN100710 RY-58 (SEQ ID Nos: 4 and 17), CPN100711 RY-59 (SEQ ID Nos: 5 and 18), CPN100877 RY-61 (SEQ ID Nos: 6 and 19), CPN100325 RY-62 (SEQ ID Nos: 7 and 20), CPN100368 RY-63 (SEQ ID Nos:8 and 21), CPN100624 RY-64 (SEQ ID Nos:9 and 22), CPN100633 RY-65 (SEQ ID Nos:10 and 23), CPN100985 RY-66 (SEQ ID Nos:11 and 24), CPN100987 RY-67 (SEQ ID Nos:12 and 25) and CPN100988 RY-68 (SEQ ID Nos:13 and 26).

VACCINE COMPOSITION

The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed Chlamydia antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100149 polypeptide of a strain of Chlamydia pneumoniae and a promoter to effect expression of the CPN100149 polypeptide in the host. Modifications are possible within the scope of this invention.

DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION

Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of Chlamydia. A non-replicating vector, including a plasmid vector, contains a nucleotide sequence encoding an STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the STK in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

ISOLATION OF PRINCIPAL OUTER MEMBRANE PROTEIN AND ANTIGEN OF CHLAMYDIA TRACHOMATIS

TYPE III SECRETION INJECTISOME PROTEINS FOR TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS

Cpn0803, CopB (Cpn0809) and CopD (Cpn0808) proteins and homologues thereof are shown to induce an immune response that is protective against a live challenge with Chlamydia. Methods and uses of Cpn0803 or fragments or epitopes thereof alone or together with CopB and/or CopD or fragments or epitopes thereof for treating or preventing chlamydial infection in a subject in need thereof are provided.

METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE

Disclosed are methods and compositions related to polypeptides comprising a fusion of the needle tip protein and translocator protein of a type III secretion apparatus (T3SA) from a type III secretion system (T3SS) of a Gram negative bacteria. Disclosed herein are fusion polypeptides comprising a fusion of a needle tip protein, such as, Bsp22, LcrV, BipD, PcrV, CT053, or CT668, or an antigenic fragment thereof; and a translocator protein, such as, BopB, YopB, BipB, PopB, CopB, or CopB2, or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria, such as, Bordetella, Burkholderia, Chlamvdia, Pseudononas, Vibrio, or Yersinia.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an PilG-like protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the PilG-like gene in the host. Modifications are possible within the scope of this invention.

TWO-STEP IMMUNIZATION PROCEDURE AGAINST CHLAMYDIA INFECTION

A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.

CHLAMYDIA ANTIGENES AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

... ▓▓▓The present invention provides purified and isolated polynucleotide molecules ▓that encode Chlamydia polypeptides which can be used in methods to prevent, ▓treat, and diagnose Chlamydia infection. In one form of the invention, the ▓polynucleotide molecules are selected from DNA that encode polypeptides ▓CPN100397 (SEQ ID Nos: 1 and 2), CPN100421 (SEQ ID Nos: 3 and 4), CPN100422 ▓(SEQ ID Nos: 4 and 6), CPN100424 (SEQ ID Nos: 7 and 8), CPN100426 (SEQ ID Nos: ▓9 and 10), CPN100508 (SEQ ID Nos: 11 and 12), CPN100515 (SEQ ID Nos: 13 and ▓14), CPN100538 (SEQ ID Nos: 15 and 16), CPN100557 (SEQ ID Nos: 17 and 18), ▓CPN100622 (SEQ ID Nos: 19 and 20), CPN100626 (SEQ ID Nos: 21 and 22), ▓CPN100628 (SEQ ID Nos: 23 and 24) and CPN100630 (SEQ ID Nos: 25 and 26).▓ ...

STRUCTURED SYNTHETIC ANTIGEN LIBRARIES AS DIAGNOSTICS, VACCINES AND THERAPEUTICS

The present invention relates to "structured synthetic antigen libraries" (SSAL) composed of related peptides synthesized simultaneously in a single peptide synthesis. This "stuctured" library contrasts to those libraries previously described as "random peptide libraries" in that the order or structure within a synthetic antigen is provided by invariant amino acid residues that define the framework sequence of the synthetic antigen. The specific amino acids and their frequency of appearance at a variant locus within aligned peptide sequences is defined by the primary sequences of the several variants that make up the alignment used to construct the antigen peptide library. A method of constructing an open diagnostic, vaccine or therapeutic for a mutational infectious agent is also provided. The invention further provides the SSAL in diagnostic methods, kits vaccination methods, vaccine compositions and pharmaceutical compositions. The libraries are prepared from variable domains in proteins ...

SYNTHETIC PEPTIDE VACCINE FOR CHLAMYDIA TRACHOMATIS

A synthetic peptide capable of producing an immunological response to C. trachomatis in a vertebrate is disclosed. The synthetic peptide comprises at least one conserved T-helper cell stimulating epitope located within the peptide sequence ALNIWDRFDVFCTLGATTGYLKGNS and at least one B-cell neutralizing antibody stimulating epitope located within the peptide sequence FDVTTLNPTIAGAGDVK. In a preferred embodiment, the epitopes are colinear and in a particularly preferred embodiment the T-helper cell stimulating epitope is located closer to the N-terminus of the peptide than the B-cell neutralizing antibody stimulating epitope.

RECOMBINANT PGP3, METHODS OF PREPARATION AND USE IN DIAGNOSIS AND THERAPY

... new recombinant form of the plasmid-encoded protein pgp3 from C.trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format.

NOVEL RATC

The invention provides ratC polypeptides and DNA (RNA) encoding ratC polypeptide s and methods for producing such polypeptides by recombinant techniques. Also prov ided are methods for utilizing ratC polypeptides to screen for antibacterial compounds.

ВАКЦИНЫ ПРОТИВ ХЛАМИДИОЗА

Настоящее изобретение относится к композициям, содержащим белки или полинуклеотиды Chlamydia sp., в частности комбинации белков или кодирующих их полинуклеотидов, и к способам применения данных белков или полинуклеотидов в лечении, предупреждении или диагностике хламидиоза.

ВАКЦИНЫ ПРОТИВ ХЛАМИДИОЗА

Настоящее изобретение относится к композициям, содержащим белки или полинуклеотиды Chlamydia sp., в частности, комбинации белков или кодирующих их полинуклеотидов, и к способам применения данных белков или полинуклеотидов в лечении, предупреждении или диагностике хламидиоза.

Compounds for detection of infection by chlamydophila abortus

Compounds and methods for treatment and diagnosis of chlamydial infection

PEPTIDES FOR CHLAMYDOPHILA PNEUMONIAE VACCINE AND DIAGNOSIS

Peptides are disclosed that include SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, or a conservative variant or mimic thereof, wherein the conservative variant or mimic specifically binds an antibody that specifically binds SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. These peptides are of use in generating an immune response against C. pneumoniae.

METHOD FOR IDENTIFYING SECRETED CHLAMYDIA POLYPEPTIDES BY USING A TYPE III SECRETION SYSTEM OF A GRAM-NEGATIVE

Chlamydia spp. are strictly intracellular pathogens that grow inside a vacuole, called an inclusion. They possess genes encoding proteins homologous to components of type III secretion machineries which, in other bacterial pathogens, are involved in delivery of bacterial proteins within or through the membrane of eukaryotic host cells. Inc proteins are chlamydial proteins that are associated with the membrane of the inclusion and are characterized by the presence of a large hydrophobic domain in their amino acid sequence. To investigate whether some Chlamydia proteins, especially Inc proteins and other proteins exhibiting a similar hydropathic profile, might be secreted, the inventors used an heterologous secretion system, namely a type III system. Chimeras were constructed by fusing the N-terminal part of these proteins with a reporter, the Cya protein of Bordetella pertussis, and expressed in various strains of Shigella flexneri. The inventors demonstrate that these hybrid proteins are ...

VACCINE ANTIGENS AGAINST INFECTION BY CHLAMYDIA TRACHOMATIS

Immunogenic peptides derived from Chlamydia trachomatis are provided. Their use in vaccines is described as are the vaccines themselves and methods of vaccinating subjects using such vaccines.

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

La présente invention concerne un procédé d'immunisation par acides nucléiques (y compris par ADN) d'hôtes (y compris les humains) contre les maladies provoquées par l'infection par une souche de Chlamydia, notamment de C. pneumoniae, au moyen d'un vecteur contenant une séquence nucléotidique contenant une protéine de membrane extérieure de 98 kDa appartenant à la souche de C. pneumoniae et un promoteur assurant l'expression chez l'hôte du gène de la protéine de membrane extérieure de 98 kDa. Des modifications sont possibles dans le cadre de cette invention.

DNA IMMUNIZATION AGAINST <i>CHLAMYDIA</i> INFECTION

On utilise l'immunisation par acide nucléique, dont l'ADN, pour générer une réponse immunitaire protectrice dans un hôte, dont l'humain, contre une sérine-thréonine kinase (STK) d'une souche de Chlamydia. Un vecteur ne se répliquant pas, dont un vecteur plasmide, contient une séquence nucléotidique codant pour une STK ou un fragment de la STK qui génère des anticorps réagissant spécifiquement avec STK et un promoteur couplé activement à la première séquence nucléotidique pour l'expression de STK dans l'hôte. Le vecteur ne se répliquant pas peut être combiné à un excipient acceptable au plan pharmaceutique, en vue d'une administration in vivo à l'hôte.

Chlamydia flagellar protein antigen

The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules encode polypeptides CPN100988 RY-68 (SEQ ID Nos:13 and 26).

Salmonella vectored vaccines against Chlamydia and methods of use

The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.

CHLAMYDIA ANTIGENS

Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.

Identification of essential genes in microorganisms

The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate molecules for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms.

Chlamydia antigens and corresponding DNA fragments and uses thereof

The present invention provides a vaccine for immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine contains a polypeptide comprising an omp P6 precursor sequence of a strain of C. pneumoniae and variants of the sequence. Modifications are possible within the scope of this invention.

Chlamydia pneumoniae polynucleotides and uses thereof

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said ...

Compositions and methods for removal of detergents

Compounds having detergent properties are disclosed. When a modifying reagent is brought into contact with these compounds, the detergent properties are decreased. These compounds are useful, for example, as solubilizing agents for microbial antigens and/or antibodies and for reversibly wetting hydrophobic surfaces. Accordingly, methods are disclosed for increasing the hydrophilic properties of a material, such as a microbial antigen and/or antibody, the methods generally comprising the steps of contacting the material with the compound having detergent properties and a modifiable group, and modifying the compound with a modifying reagent. Kits are also disclosed for use in accordance with this methodology.

Vault Compositions for Immunization

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

Porin B (PorB) as a Therapeutic Target for Prevention and Treatment of Infection by Chlamydia

The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia -neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.

CHIMERIC MOMP ANTIGEN

The present invention regards polypeptides capable of eliciting an immunological response that is protective against The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided. 1. A polypeptide comprising a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2 , wherein said first and second amino acid sequences are separated by less than 30 amino acid residues.2. The polypeptide according to claim 1 , wherein the first amino acid sequence has at least 95% homology with the amino acid sequence according to SEQ ID NO: 1 and the second amino acid sequence which has at least 95% homology with the amino acid sequence according to SEQ ID NO: 2.3. The polypeptide according to claim 1 , which is between 107 and 132 amino acids long.4. The polypeptide according to claim 1 , wherein the first amino acid sequence and the second amino acid sequence are separated by a linker according to SEQ ID NO: 20 or SEQ ID NO: 26.5. The polypeptide according to claim 1 , wherein the first amino acid sequence is a sequence according to SEQ ID NO: 21 or SEQ ID NO: 23 claim 1 , and the second amino acid sequence is a sequence according to SEQ ID NO: 22 or SEQ ID NO: 24.6. The polypeptide according to which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 3.7. (canceled)8. The polypeptide according to claim 6 , comprising an amino acid sequence according to SEQ ID NO: 3.9. The polypeptide according to claim 1 , fused to an amino acid sequence comprising a His tag according to SEQ ...

VACCINES AGAINST CHLAMYDIAL INFECTION

The present invention relates to compositions comprising proteins or polynucleotides of sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of infection. 1. A composition comprising{'i': 'Chlamydia', 'i. a combination of two or more proteins or immunogenic fragments thereof selected from the group consisting of Ct-858, Ct-875, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd) or polynucleotides encoding them, and'}ii. a pharmaceutically acceptable carrier.2ChlamydiaChlamydia. A composition according to which comprises a Ct-089 protein or an immunogenic fragment thereof claim 1 , and a Ct-858 protein or an immunogenic fragment thereof.3Chlamydia. A composition according to further comprising a Ct-875 protein or an immunogenic fragment thereof.5Chlamydia. A composition according to further comprising a PmpDpd protein or an immunogenic fragment thereof.6. A composition according to claim 1 , wherein the composition is an immunogenic composition.7. A composition according to further comprising an adjuvant.8. A composition according to wherein the adjuvant is a preferential stimulator of a Th1 response.9. A composition according to wherein the adjuvant comprises 3D-MPL claim 8 , QS21 or a combination of 3D-MPL and QS21.10. A composition according to wherein the adjuvant further comprises an oil in water emulsion.11. A composition according to wherein the adjuvant further comprises liposomes.12. A composition according to wherein two or more of the proteins or immunogenic fragments are linked to form a fusion protein.13Chlamydia. A composition comprising one of the following combinations of polypeptides or immunogenic fragments thereof:a) Two out of: Ct-858, Ct-875, Ct-089, PmpDpd, PmpGpd;b) Ct-858, Ct-875, Ct-089; andc) PmpDpd, Ct-858, Ct-875, Ct-089.14. A composition according to claim 1 , wherein:a) Ct-089 is a ...

Chlamydia vaccine

Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.

METHODS AND COMPOSITIONS FOR ATTENUATED CHLAMYDIA AS VACCINE AND VECTOR

The present invention provides organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors. 2Chlamydia trachomatis. The isolated cell of claim 1 , wherein the substitution in open reading frame CT849 is Q117E.3Chlamydia trachomatis. The isolated cell of claim 1 , wherein the substitution in open reading frame CT389 is G322R.5Chlamydia trachomatis. The isolated cell of any of claim 1 , further comprising a heterologous nucleic acid molecule.6Chlamydia trachomatis. A composition comprising the isolated cell of and a pharmaceutically acceptable carrier.7Chlamydia trachomatis. A composition comprising the isolated cell of and a pharmaceutically acceptable carrier.8Chlamydia trachomatis. A method of treating and/or preventing a disorder associated with or caused by chlamydial infection in a subject claim 1 , comprising administering to the subject an effective amount of the isolated cell of .9ChlamydiaChlamydia trachomatis. A method of eliciting an immune response to in a subject claim 1 , comprising administering to the subject an effective amount of the isolated cell of .10ChlamydiaChlamydia trachomatis. A method of reducing the likelihood of infertility due to infection in a subject claim 1 , comprising administering to the subject an effective amount of the isolated cell of .11ChlamydiaChlamydia trachomatis. A method of reducing the incidence of hydrosalpinx due to infection in a subject claim 1 , comprising administering to the subject an effective amount of the isolated cell of .12. The method of claim 1 , further comprising administering an adjuvant to the subject.13Chlamydia trachomatis. A method of delivering a heterologous nucleic acid molecule to a subject claim 5 , comprising administering to the subject the cell of .14. The method of claim 13 , wherein the heterologous nucleic acid molecule encodes a therapeutic protein or therapeutic RNA. ...

IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS

A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet. 1. A cell comprising at least one unnatural nucleic acid , wherein at least one unnatural nucleic acid is an imported unnatural nucleic acid.2. The cell of claim 1 , further comprising an expanded genetic alphabet claim 1 , wherein the genetic alphabet is comprised of at least one unnatural base pair (UBP).3. The cell of further comprising a heterologous nucleic acid.4. The cell of claim 3 , wherein a heterologous nucleic acid encodes for a nucleotide triphosphate transporter (NTT).5. The cell of claim 4 , wherein the heterologous NTT transports a least one unnatural nucleic acid into the cell.6. The cell of claim 1 , wherein the cell comprises enhanced import of an unnatural nucleotide claim 1 , enhanced incorporation of an unnatural nucleotide into a nucleic acid of the cell claim 1 , or decreased degradation of an unnatural nucleic acid in comparison to the respective wild type cell.7. The cell of claim 6 , wherein the cell further comprises at least one template UBP comprising at least one unnatural template nucleic acid.8. The cell of claim 7 , wherein at least one unnatural nucleic acid comprises an unnatural base.9. The cell of claim 8 , wherein the unnatural base is selected from the group consisting of 2-aminoadenin-9-yl claim 8 , 2-aminoadenine claim 8 , 2-F-adenine claim 8 ...

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a infection. 114-. (canceled)15. A vaccine comprising at least one epitope identified by a method of determining whether a library contains or encodes an immunogenic polypeptide , wherein said library comprises at least 20 discrete members in defined locations and said members each comprise a cell or virus comprising a pre-determined open reading frame of a polynucleotide encoding a polypeptide , or a portion thereof , differentially expressed in a neoplastic cell as compared to a corresponding normal cell , said pre-predetermined open reading frame operably linked to a promoter ,said method comprising:(a) individually contacting a member of said library with a second cell capable of (i) endocytosing said cell or said virus and (ii) displaying a polypeptide encoded by said pre-determined open reading frame on its surface through the major histocompatibility complex (MHC class) I pathway;(b) individually contacting each member of step (a) with a cytotoxic T lymphocyte (CTL) cell derived from a mammal having, or having previously had, a neoplasm;(c) detecting whether said CTL cell is activated, wherein activation of said CTL cell indicates that said member of said library contains said pre-determined open reading frame which encodes at least a portion of said immunogenic polypeptide; and(d) identifying an epitope sufficient for CTL activation within said polypeptide, or portion thereof, determined to be immunogenic in step (c),further comprising a pharmaceutically acceptable carrier.16. An epitope cocktail comprising at least 5 epitopes identified using a method of determining whether a library contains or encodes an immunogenic polypeptide , wherein said library comprises at least 20 discrete members in defined ...

CHLAMYDIA ANTIGENS

antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as , in a subject. 1. An isolated CT491 polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO: 1 , or fragment thereof , wherein said polypeptide or fragment elicits at least an 40-fold increase in interferon-γ production from a population of T-lymphocytes compared to the level of interferon-γ production elicited from a non-antigenic peptide in the same assay.2. The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment claim 1 , when administered to a mammal claim 1 , elicits an immune response.3. The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment elicits a CD8 T-cell response.4. The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment comprises at least one flanking amino acid.5. The fragment of claim 1 , wherein said fragment is fewer than 400 amino acids in length.6. The fragment of claim 5 , wherein said fragment is fewer than 300 amino acids in length.7. The fragment of claim 6 , wherein said fragment is fewer than 200 amino acids in length.8. The fragment of claim 7 , wherein said fragment is fewer than 100 amino acids in length.9. The fragment of claim 8 , wherein said fragment is fewer than 50 amino acids in length.10. The fragment of claim 9 , wherein said fragment is fewer than 30 amino acids in length.11. The fragment of claim 10 , wherein said fragment is fewer than 15 amino acids in length.12. The polypeptide or fragment of claim 1 , wherein said polypeptide or fragment contains at least one conservative amino acid substitution in the sequence of SEQ ID NO: 1.13. The polypeptide or fragment of claim 12 , wherein said polypeptide or fragment comprises at least one flanking amino acid.14. The polypeptide or fragment of claim 12 , wherein said polypeptide or ...

CHLAMYDIA ANTIGEN COMPOSITIONS AND USES THEREOF

The present invention provides in part fusion proteins derived from spp. The present invention also provides in part methods for treating or preventing infection using the fusion proteins. 1Chlamydia. An immunogenic composition comprising a fusion protein which comprises at least two proteins selected from: Polymorphic membrane protein G (PmpG) , Polymorphic membrane protein F (PmpF) , Polymorphic membrane protein E (PmpE) , Polymorphic membrane protein H (PmpH) , Ribosomal protein L6 (RplF) , Anti-anti-sigma factor (Aasf) , Translocated actin-recruiting phosphoprotein (Tarp) , hypothetical protein corresponding to locus tag CT143/TC0420 , metalloprotease , insulinase family (CT806/TC0190) , hypothetical protein corresponding to locus tag CT538/TC0825 , hypothetical protein corresponding to locus tag CT017/TC0285 , hypothetical protein corresponding to locus tag CT619 , or MOMP , or an immunogenic fragment thereof , together with a physiologically acceptable carrier.2. The composition of wherein the fusion protein comprises PmpG and MOMP.3. The composition of wherein the fusion protein comprises PmpG and PmpF.4. The composition of wherein the fusion protein comprises PmpG and PmpH.5. The composition of wherein the fusion protein comprises PmpE and PmpF.6. The composition of further comprising an adjuvant.7. The composition of wherein the adjuvant is selected from DDA/TDB claim 6 , DDA/MMG or DDA/MPL.8Chlamydia. A method for eliciting an immune response against a spp. claim 1 , or component thereof claim 1 , in an animal comprising administering to the animal an effective amount of the composition of claim 1 , thereby eliciting an immune response in the animal.9. The method of wherein the immune response is a cellular immune response.10ChlamydiaChlamydia. A method for treating or preventing infection by a spp. in an animal comprising administering to the animal an effective amount of the composition of claim 1 , thereby treating or preventing infection by the spp. in ...

METHOD AND PEPTIDES FOR THE DETECTION OF CHLAMYDIA SUIS

The present invention relates to a method and kit for detecting and diagnosing infections in a subject using peptides comprising the amino acid sequence of GTKDASID and/or SQQSSIAS as antigenic determinants. 1Chlamydia suis. An in vitro method for detecting the presence of antibodies in a subject , comprising:providing a biological sample from the subject, and{'claim-ref': {'@idref': 'CLM-00008', 'claim 8'}, 'analyzing the sample for the presence of antibodies against one or both of the peptides according to .'}2Chlamydia suis. The method according to claim 1 , whereby the presence of antibodies against one or both peptides is indicative for a past claim 1 , early or late infection in the subject.3. The method according to claim 1 , characterized in that the biological sample from the subject is a body fluid.4. The method according to claim 1 , characterized in that the detected antibodies are of the IgA claim 1 , IgM and/or IgG type.5. The method according to claim 1 , characterized in that the subject is a mammal claim 1 , in particular a pig.6. The method according to claim 1 , characterized in that the presence of antibodies is detected by use of an immunoassay.7. The method according to claim 6 , wherein the immunoassay is an enzyme linked immunosorbent assay (ELISA).8. An isolated peptide of 8 to 30 amino acids long claim 6 , comprising an amino acid sequence represented by SEQ ID NO: 1 (GTKDASID) or by SEQ ID NO: 2 (SQQSSIAS) claim 6 , or a sequence at least 75% identical thereto.9. The peptide according to claim 8 , wherein said peptide is an antigenic peptide.10. The peptide according to claim 8 , consisting of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 claim 8 , or a sequence at least 75% identical thereto.11Chlamydia suis. A kit for use in the diagnosis of a infection claim 8 , comprising one or both of the peptides according to claim 8 , wherein said peptide(s) are immobilized on a solid support.12. The kit according to claim 11 ...

RECOMBINANT EXPRESSION OF CHLAMYDIA MOMP ANTIGEN

The present invention relates to methods for the recombinant expression of major outer membrane protein (MOMP) comprising transforming a population of host cells with an expression vector comprising a nucleic acid molecule that encodes MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of infection and/or the effects thereof. 1Chlamydia. A method for the recombinant expression of major outer membrane protein (MOMP) comprising:{'i': E. coli', 'chlamydia, '(a) transforming a population of host cells with an expression vector comprising a nucleic acid molecule comprising a sequence of nucleotides that encode a leader sequence for targeting the MOMP to the outer membrane of the cell and a sequence of nucleotides that encode MOMP, wherein the nucleic acid molecule is operatively linked to a promoter;'}{'i': 'Chlamydia', '(b) culturing the transformed cells under conditions that permit expression of the nucleic acid molecule and translocation to the outer membrane of the cells to produce a recombinant MOMP; and'}(c) optionally purifying the MOMP.2E. coli. The method of claim 1 , wherein the sequence of nucleotides that encodes the MOMP is codon harmonized or codon optimized for optimal expression in an host cell.3. The method of claim 1 , wherein the leader sequence is operatively linked to the N-terminus of the MOMP.4. The method of claim 1 , wherein the leader sequence is directly adjacent to the MOMP sequence.5. The method of claim 1 , wherein the nucleic acid molecule further comprises a sequence of ...

Compositions for and methods of identifying antigens

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.

RECOMBINANT EXPRESSION OF CHLAMYDIA MOMP ANTIGEN

The present invention relates to methods for the recombinant expression of major outer membrane protein (MOMP) comprising transforming a population of host cells with an expression vector comprising a nucleic acid molecule that encodes MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of infection and/or the effects thereof. 121.-. (canceled)22Chlamydia. A nucleic acid molecule comprising a sequence of nucleotides that encodes major outer membrane protein (MOMP) comprising a nucleotide sequence that is codon harmonized relative to the wild-type nucleotide sequence encoding the same MOMP.23. The nucleic acid molecule of claim 22 , further comprising a nucleotide sequence that encodes a leader sequence for targeting the MOMP to the outer membrane of a cell claim 22 , wherein the leader sequence is operatively linked to the N-terminus of the MOMP.24. The nucleic acid molecule of which comprises a sequence of nucleotides as set forth in SEQ ID NO:15 claim 23 , SEQ ID NO:18 claim 23 , or SEQ ID NO:21.2526-. (canceled)27. The nucleic acid molecule of claim 22 , wherein the nucleic acid molecule encodes a MOMP protein comprising the sequence of amino acids as set forth in any of SEQ ID Nos: 24-31.28. The nucleic acid molecule of claim 23 , wherein the nucleic acid molecule encodes a leader sequence comprising the amino acid sequence set forth in any of SEQ ID Nos: 8-13.29. The nucleic acid molecule of claim 28 , wherein the nucleic acid molecule encodes a leader sequence comprising the amino acid sequence set ...

CHLAMYDIA ANTIGENS

The invention provides antigens for use in the treatment, prevention and/or diagnosis of infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from for the treatment, prevention or diagnosis of infection. 1. A protein comprising the amino acid sequence of any one of SEQ ID NO: 2 , SEQ ID NO:4 , SEQ ID NO:6 , SEQ ID NO:8 , SEQ ID NO:10 , SEQ ID NO:12 , SEQ ID NO:14 , SEQ ID NO:16 , SEQ ID NO: 18 , SEQ ID NO:40 , SEQ ID NO:42 , SEQ ID NO:44 , SEQ ID NO:46 , SEQ ID NO: 48 , SEQ ID NO:50 , SEQ ID NO:52 , SEQ ID NO:54 , SEQ ID NO:136 or SEQ ID NO:140 for use in therapy or diagnosis.2. A protein having 50% or greater sequence identity to a protein according to .3. A protein comprising a fragment of the amino acid sequence of .4. A protein according to claim 3 , wherein the fragment comprises at least 8 consecutive amino acids of the amino acid sequence of SEQ ID NO: 2 claim 3 , SEQ ID NO:4 claim 3 , SEQ ID NO:6 claim 3 , SEQ ID NO:8 claim 3 , SEQ ID NO:10 claim 3 , SEQ ID NO:12 claim 3 , SEQ ID NO:14 claim 3 , SEQ ID NO:16 claim 3 , SEQ ID NO: 18 claim 3 , SEQ ID NO:40 claim 3 , SEQ ID NO:42 claim 3 , SEQ ID NO:44 claim 3 , SEQ ID NO:46 claim 3 , SEQ ID NO: 48 claim 3 , SEQ ID NO:50 claim 3 , SEQ ID NO:52 claim 3 , SEQ ID NO:54 claim 3 , SEQ ID NO:136 or SEQ ID NO:140.5. An antibody which binds to a protein according to for use in therapy or diagnosis.6. A nucleic acid molecule which encodes a protein or antibody according to for use in therapy or diagnosis.7. A nucleic acid molecule according to claim 6 , comprising the nucleotide sequence of any one of SEQ ID NO: 1 claim 6 , SEQ ID NO:3 claim 6 , SEQ ID NO:5 claim 6 , SEQ ID NO:7 claim 6 , SEQ ID NO:9 claim 6 , SEQ ID NO:11 claim 6 , SEQ ID NO:13 claim 6 , SEQ ID NO:15 claim 6 , SEQ ID NO:17 claim 6 , SEQ ID NO:39 claim 6 , SEQ ID NO:41 claim 6 , ...

IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS

A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet. 2. The cell of claim 1 , wherein the nucleoside triphosphate transporter is engineered to transport the triphosphates of the first unnatural nucleotide and the second unnatural nucleotide into the cell.3. The cell of claim 1 , wherein the nucleoside triphosphate transporter comprises an amino acid sequence with at least about 90% sequence identity to SEQ ID NO: 1.13Escherichia coli. An cell comprising:(a) deoxyribonucleic acid (DNA) comprising at least one unnatural base pair (UBP), wherein the at least one UBP comprises a first unnatural nucleotide and a second unnatural nucleotide; and(b) a heterologous nucleoside triphosphate transporter comprising an amino acid sequence that is at least about 85% identical to SEQ ID NO: 1.14. The cell of claim 13 , wherein the first unnatural nucleotide and the second unnatural nucleotide each independently comprise a base selected from the group consisting of 2-aminoadenin-9-yl claim 13 , 2-aminoadenine claim 13 , 2-F-adenine claim 13 , 2-thiouracil claim 13 , 2-thio-thymine claim 13 , 2-thiocytosine claim 13 , 2-propyl and alkyl derivatives of adenine and guanine claim 13 , 2-amino-adenine claim 13 , 2-amino-propyl-adenine claim 13 , 2-aminopyridine claim 13 , 2-pyridone claim 13 , 2′-deoxyuridine claim 13 , 2-amino-2′-deoxyadenosine 3- ...

Vaccines against Chlamydia sp.

The present invention describes an efficient vaccine against a (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system. 1Chlamydia: A polypeptide comprising 3 or more immuno-repeat units of surface exposed fragments of the major outer membrane protein (MOMP), wherein each immuno-repeat comprises an amino acid sequence which comprises the variable domain 4 (VD4) region of the MOMP chosen from any sp. serotype. The present invention relates to polypeptides of repetitive units of immunogenic fragments of surface exposed regions of outer membrane proteins of sp. and pharmaceutical compositions and vaccines comprising these fusion proteins.Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. is responsible for human acute respiratory infection and believed to play a role in coronary heart disease. is the causative agent of human sexually transmitted disease and eye infections (Trachoma). Also in animals, several infections with sp. are known, e.g. infecting pigs, and which causes abortion in small ruminants (sheep and goats).Worldwide, it is estimated that 92 million individuals become sexually infected with (Ct). Urogenital infections with Ct are of public health concern because of its high prevalence and the fact that it's a risk factor for ectopic pregnancy and infertility. In addition to this Ct infections have been shown to facilitate the transmission of HIVand act as a co-factor in HPV-induced cervical carcinoma. The duration of untreated genital Ct infection can be prolonged, and complete clearance is often not reached within the first 12 months. From human studies it is known that some ...

CHLAMYDIA NANOEMULSION VACCINE

The present application relates to the field of human immunology, in particular, a chlamydia vaccine. The subunit vaccine composition may comprise isolated antigens from chlamydia bacteria, fusion proteins or fragments thereof, live or attenuated bacteria, or other bacterial components mixed in varied combination with a nanoemulsion, which provides a potent immune enhancer. 1. A vaccine composition comprising:(a) an immune enhancing nanoemulsion, wherein the nanoemulsion comprises an oil-in-water nanoemulsion or a dilution thereof; and(b) at least one chlamydia bacteria antigen, wherein the chlamydia bacteria antigen is whole chlamydia, an isolated chlamydia antigen, a recombinant chlamydia antigen, or a combination thereof, and wherein the chlamydia bacteria antigen is present within the nanoemulsion.2. The vaccine composition of claim 1 , wherein the chlamydia bacteria antigen is inactivated prior to incorporation into a nanoemulsion and/or where the chlamydia antigen is inactivated by the nanoemulsion.3. The vaccine composition of claim 1 , wherein the chlamydia bacteria antigen is derived from chlamydia bacteria and comprises at least one major outer-membrane protein (MOMP) claim 1 , chlamydial outer-membrane complex (COMC) claim 1 , polymorphic outer-membrane proteins (POMPs or Pmps) claim 1 , the 60 and 75 kDa heat-shock proteins claim 1 , the type-III secretory system structural proteins claim 1 , exoglycolipid claim 1 , Inc proteins claim 1 , Cap1 claim 1 , CT111 claim 1 , CT242 claim 1 , CT687 claim 1 , CT823 claim 1 , or CT144 or an immunogenic fragment thereof.4. The vaccine composition of claim 1 , wherein one or more chlamydia antigens further comprise nucleotide modifications denoting attenuating phenotypes.5. The vaccine composition of claim 1 , wherein at least one chlamydia antigen is present in a fusion protein.6. The vaccine composition of claim 1 , wherein at least one chlamydia antigen is present in an immunogenic peptide fragment of major outer ...

CHLAMYDIA ANTIGENS

The invention provides antigens for use in the treatment, prevention and/or diagnosis of infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from for the treatment, prevention or diagnosis of infection. 1. An isolated protein comprising an amino acid sequence of any one of SEQ ID NO: 2 , SEQ ID NO:4 , SEQ ID NO:6 , SEQ ID NO:8 , SEQ ID NO: 10 , SEQ ID NO: 12 , SEQ ID NO: 14 , SEQ ID NO: 16 , SEQ ID NO: 18 , SEQ ID NO:40 , SEQ ID NO:42 , SEQ ID NO:44 , SEQ ID NO:46 , SEQ ID NO: 48 , SEQ ID NO:50 , SEQ ID NO:52 , SEQ ID NO:54 , SEQ ID NO: 136 or SEQ ID NO: 140 for use in therapy or diagnosis.2. An isolated protein having 50% or greater sequence identity to a protein according to .3. An isolated protein comprising a fragment of the amino acid sequence of .4. The protein according to claim 1 , wherein the fragment comprises at least 8 consecutive amino acids of the amino acid sequence of .5. An antibody which binds to the protein according to for use in therapy or diagnosis.6. A nucleic acid molecule which encodes the protein according for use in therapy or diagnosis.7. The nucleic acid molecule according to claim 6 , comprising the sequence of any one of SEQ ID NO: 1 claim 6 , SEQ ID NO:3 claim 6 , SEQ ID NO:5 claim 6 , SEQ ID NO:7 claim 6 , SEQ ID NO:9 claim 6 , SEQ ID NO: 11 claim 6 , SEQ ID NO:13 claim 6 , SEQ ID NO: 15 claim 6 , SEQ ID NO: 17 claim 6 , SEQ ID NO:39 claim 6 , SEQ ID NO:41 claim 6 , SEQ ID NO:43 claim 6 , SEQ ID NO:45 claim 6 , SEQ ID NO:47 claim 6 , SEQ ID NO:49 claim 6 , SEQ ID NO:51 claim 6 , SEQ ID NO:53 claim 6 , SEQ ID NO: 135 or SEQ ID NO: 139.8. A nucleic acid molecule comprising of a fragment of the nucleotide sequence of any one of SEQ ID NO: 1 claim 6 , SEQ ID NO:3 claim 6 , SEQ ID NO:5 claim 6 , SEQ ID NO:7 claim 6 , SEQ ID NO:9 claim 6 , SEQ ID NO: 11 claim 6 , ...

Vaccines for chlamydia

The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus Chlamydia . In particular, the present invention relates to isolated B- and T-cell epitopes derived from the major outer membrane protein of Chlamydia psittaci which can be used against an infection with a species of the genus Chlamydia . More in particular, the invention provides a vaccine which can be used against chlamydiosis caused by Chlamydia psittaci in birds and man. In addition, the invention relates to a diagnostic method to diagnose the latter infections.

Vaccines against Chlamydia sp.

The present invention describes an efficient vaccine against a (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system. 1Chlamydia. A polypeptide comprising 3 or more immuno-repeat units of surface exposed fragments of the major outer membrane protein (MOMP) , wherein each immuno-repeat comprises an amino acid sequence which comprises the variable domain 1 (VD1) region of the MOMP chosen from any species serotype , wherein the amino acid sequences are optionally linearized.2. The polypeptide according to claim 1 , wherein the immuno-repeats are homologous.3Chlamydia. The polypeptide according to claim 1 , wherein the amino acid sequences comprising the VD1 region of the MOMP from any species serotype are placed next to each other.4. The polypeptide according to claim 1 , wherein the immuno-repeats are heterologous.5ChlamydiaChlamydia pneumoniaeChlamydia trachomatis.. The polypeptide according to claim 1 , wherein the MOMP from any species serotype is from or serotype D claim 1 , E claim 1 , F claim 1 , G claim 1 , Ia or J of6Chlamydia. The polypeptide according to claim 1 , further comprising one or more of a variable domain 2 and a variable domain 3 claim 1 , each of the MOMP from any species serotype.7. The polypeptide according to claim 1 , wherein the amino acid sequences are linearized.8Chlamydia. The polypeptide according to claim 1 , wherein the amino acid sequences comprising the VD1 region of the MOMP from any species serotype are spaced with a linker.9. The polypeptide according to claim 1 , comprising an amino acid sequence defined in formula II:{'br': None, 'yy1-VD1-yy2\u2003\u2003(Formula II)'} 'VD1 is independently ...

Methods and compositions for vaccinating a subject for a sexually transmitted pathogen

Purified Chlamydia major outer membrane protein (MOMP) has been observed to induce protection against genital and respiratory challenge in mice. MOMP contains variable domains that are highly immunogenic and elicit cross-serovar neutralizing monoclonal and polyclonal antibodies and T cell responses in animal and human models. Examples herein provide a method for vaccinating a subject against Chlamydia using a composition that is a recombinant Neisseria porin that contains at least one antigenic variable domain of Chlamydia . The variable domains are inserted into the amino acid sequence of the Neisseria porin at a position encoding a surface-exposed loop of the Neisseria porin. The vaccine further contains an adjuvant that induces a Th1 response greater than a Th2 response.

Chlamydia suis diagnosis

The present invention relates to a method for detecting and diagnosing Chlamydia suis infections in a subject, and a diagnostic kit therefor.

MULTI-EPITOPIC CONSTRUCT

The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products 1. A recombinant construct comprising:(i) a scaffold portion;(ii) a first species of epitope capable of eliciting an anti-arteriosclerotic vascular disease response via a first pathway; and(iii) a second species of epitope capable of eliciting an anti-arteriosclerotic vascular disease via a second pathway that is independent from the said first pathway.2. The construct according to comprising a plurality of first and/or second species of epitopes; optionally wherein the first pathway associated with atherosclerosis formation is via a C5a or a C5aR interaction.3. (canceled)4. The construct according to claim 1 , wherein the first species of epitope is a C5a or a C5a receptor (C5aR) protein; optionally wherein the C5a epitope is a polypeptide comprising an amino acid sequence from 5 to 40 contiguous amino acid residues from SEQ ID NO:2.5. (canceled)6. The construct according to either claim 3 , wherein the C5a epitope is a polypeptide comprising an amino acid sequence selected from the group comprising claim 3 , or consisting of EQRAARISLGPR (SEQ ID NO:3) claim 3 , RAARISLGPRCIKAFTE (SEQ ID NO:4) and CVNNDETCEQ (SEQ ID NO:5) or a functional fragment thereof that has antigenic activity.7. The construct according to wherein the C5aR epitope is a polypeptide comprising an amino acid sequence from 5 to 45 contiguous amino acid residues from SEQ ID NO:6; optionally claim 4 , wherein C5aR epitope is ...

Vault Compositions for Immunization

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. 112-. (canceled)13. A vaccine comprising a pathogen immunogenic peptide or a pathogen immunogenic fragment or variant thereof incorporated within a vault-like particle , wherein the vault-like particle comprises MVP , and wherein administration of the vaccine to a subject in need thereof stimulates a cellular immune response.14. The vaccine of claim 13 , wherein the pathogen immunogenic peptide is fused to INT.15. The vaccine of claim 13 , wherein the pathogen immunogenic peptide is fused to MVP.16. The vaccine of claim 15 , wherein the pathogen immunogenic peptide is fused to the N-terminus of MVP.17. The vaccine of claim 13 , wherein the number of MVP is 1-78.18. The vaccine of claim 13 , wherein the number of MVP is 78.19. The vaccine of claim 13 , wherein the vault-like particle further comprises VPARP or modified VPARP claim 13 , or a portion of VPARP claim 13 , or a modified portion of VPARP.20. The vaccine of claim 13 , wherein the cellular immune response is induction of Th cells.21. The vaccine of claim 20 , wherein the Th cells comprise Th-1 cells.22. The vaccine of claim 13 , wherein the cellular immune response is induction of CD4 and/or CD8+ T-cells.23. The vaccine of claim 13 , wherein the cellular immune response is production of INFγ.24. The vaccine of claim 16 , wherein the vault-like particle further comprises a targeting moiety.25. The vaccine of claim 24 , further comprising an amino acid sequence added to the C-terminus of the MVP claim 24 , which results in the targeting moiety on the surface of the vault-like particle.26. The vaccine of claim 25 , wherein the targeting ...

Chlamydia antigens

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghei.

CHLAMYDIA ANTIGENES AND THEIR CORRESPONDING DNA FRAGMENTS AND USES THEREOF

표적화된 유전자 파괴 방법 및 면역원성 조성물

편성 세포내 박테리아에서의 특정 유전자의 표적화된 파괴 및 이어지는 이의 복원은 복제를 위해 숙주 세포 내부에 거주하는 것에 대한 그의 절대적 필요로 인해 여전히 매우 난제이다. 본원에서, 리케치아 병원체인 에를리키아 카페엔시스( Ehrlichia chaffeensis )의 2개의 유전자를 불활성화시킨 후, 이러한 2개의 유전자 중 하나를 복원하도록, 표적화된 대립유전자 교환 돌연변이가 생성되었다. 그 후, 이러한 방법이 에를리키아 카니스( Ehrlichia canis ) 및 아나플라즈마 파고사이토필룸( Anaplasma phagocyophilum )에서 또한 성공적으로 이용되었다. 생성된 돌연변이된 병원체는 리케치아 병원체로의 감염의 발생률 또는 중증도를 감소시키기 위한 면역원성 조성물에서 유용하다.

Chlamydia antigens

Una proteína para su uso en terapia para la infección por Chlamydia, en la que la proteína comprende: a) la secuencia de aminoácidos de SEQ ID NO: 2; o b) una secuencia de aminoácidos que tiene una identidad de secuencia del 95 % o mayor con la secuencia de aminoácidos de la SEQ ID NO: 2; o c) la secuencia de aminoácidos de SEQ ID NO: 64.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection. No accompanying figure.

Chlamydia vaccine

Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.

PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis

Specific peptide nucleic acid (PNA) probes for detecting a sexual transmitted disease caused by Neisseria gonorrhoeae or Chlamydia trachomatis comprising N-(2-aminoethyl)glycine units in amide linkage with the glycine nitrogen connected to naturally occurring nucleobases or non-naturally occurring nucleobases by a methylene carbonyl linker and said probes capable of hybridizing to 16S or 23S rRNA or rDNA of Neisseria gonorrhoeae or Chlamydia trachomatis are described. PNA is a very stable molecule with very high affinity for nucleic acid allowing a PNA probe to be shorter than conventional nucleic acid probes.

Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes

Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis . In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.

Chlamydia antigens

The present invention relates to isolated nucleic acid molecules which encode an antigen from a Chlamydia species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Chlamydia species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by Chlamydia pneumoniae. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection with Chlamydia and methods for the treatment or prevention of an infection with Chlamydia.

DNA molecules encoding pgp3 protein from Chlamydia trachomatis

A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis , serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

Recombinant Chlamydia trachomatis PGP3 antigen

A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis , serotype D, to be used in immunogenic compositions and in the preparation of immunogenic compositions was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunoassay

A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis , serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

Recombinant Chlamydia trachomatis pgp3 protein suitable for enzyme-linked immunoassay, and used of the protein in eliciting and diagnosing an immune response

Uses of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format, in methods of eliciting and diagnosing an immune response are described.

Systems, methods, and compositions for targeted nucleic acid editing

本公开提供了用于靶向和编辑核酸的系统、方法和组合物。特别地，本发明提供了非天然存在的或工程化的RNA靶向系统，所述系统包含靶向RNA的Cas13蛋白、至少一种指导分子和至少一种腺苷脱氨酶蛋白或其催化结构域。

Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics

The present invention relates to 'structured synthetic antigen libraries' (SSAL) composed of related peptides synthesized simultaneously in a single peptide synthesis. This 'structured' library contrasts to those libraries previously described as 'random peptide libraries' in that the order or structure within a synthetic antigen is provided by invariant amino acid residues that define the framework sequence of the synthetic antigen. The specific amino acids and their frequency of appearance at a variant locus within aligned peptide sequences is defined by the primary sequences of the several variants that make up the alignment used to construct the antigen peptide library. A method of constructing an open diagnostic, vaccine or therapeutic for a mutational infectious agent is also provided. The invention further provides the SSAL in diagnostic methods, kits, vaccination methods, vaccine compositions and pharmaceutical compositions. The libraries are prepared from variable domains in proteins and provide improved vaccines, diagnostics and therapeutics for infectious agents, etc., from such proteins.

Salmonella vectored vaccines against chlamydia and methods of use

The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.

Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)

Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae , employing a vector, containing a nucleotide sequence encoding a inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host. Modifications are possible within the scope of this invention.

Nucleic acid molecules encoding POMP91A protein of Chlamydia

An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.

Chlamydia secretory locus orf and uses thereof

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C . pneumoniae . The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia pneumoniae operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from C . pneumoniae and are selected from an ATP-binding cassette protein, a secretory locus ORF, an endopeptidase, a protease, a metalloprotease, CLP protease ATPase, a CLP protease subunit, a translycolase/transpeptidase, a CLPc protease and thioredoxin.

CT062, a Chlamydia antigen

Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.

Chlamydia trachomatis antigens for vaccine and diagnostic use

OMV vaccines

The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.

Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia

An isolated and purified nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.

Chlamydia secretory locus orf and uses thereof

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C . pneumoniae . The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia pneumoniae operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from C . pneumoniae and are selected from an ATP-binding cassette protein, a secretory locus ORF, an endopeptidase, a protease, a metalloprotease, CLP protease ATPase, a CLP protease subunit, a translycolase/transpeptidase, a CLPc protease and thioredoxin.

Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

The present invention relates to an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: (a) the nucleotide sequence of ORF923; (b) a nucleotide sequence exhibiting at least 99. 9% identity with ORF923 ; or (c) a nucleotide sequence which hybridizes to ORF923 under conditions of high stringency (d) a fragment of any one of (a) to (c) which is greater than 20 nucleotides in length.

Chlamydia antigens

The invention provides identifies Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTl 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

The present invention relates to an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: (a) the nucleotide sequence of ORF52; (b) a nucleotide sequence exhibiting at least 99. 9% identity with ORF52 ; or (c) a nucleotide sequence exhibiting at least 80% homology to ORF52; or (d) a nucleotide sequence which hybridizes to ORF52 under conditions of high stringency (e) a fragment of any one of (a) to (d) which is greater than 20 nucleotides in length.

Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

The present invention relates to an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: (a) the nucleotide sequence of ORF508; (b) a nucleotide sequence exhibiting at least 99. 9% identity with ORF508 ; or (c) a nucleotide sequence exhibiting at least 80% homology to ORF508; or (d) a nucleotide sequence which hybridizes to ORF508 under conditions of high stringency (e) a fragment of any one of (a) to (d) which is greater than 20 nucleotides in length.

Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

The present invention relates to an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: (a) the nucleotide sequence of ORF693; (b) a nucleotide sequence exhibiting at least 99.9% identity with ORF693 : or (c) a nucleotide sequence exhibiting at least 80% homology to ORF693; or (d) a nucleotide sequence which hybridizes to ORF693 under conditions of high stringency (e) a fragment of any one of (a) to (d) which is greater than 20 nucleotides in length.

Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

The present invention relates to an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: (a) the nucleotide sequence of ORF347; (b) a nucleotide sequence exhibiting at least 99. 9% identity with ORF347 ; or (c) a nucleotide sequence which hybridizes to ORF347 under conditions of high stringency (d) a fragment of any one of (a) to (c) which is greater than 20 nucleotides in length.

Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia , specifically C. pneumoniae , employing a vector, containing a nucleotide sequence encoding an inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host.

Chlamydia antigens

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

Detection of Ribosomal RNA using PNA probes

PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis. Specific peptide nucleic acid (PNA) probes for detecting a sexual transmitted disease caused by Neisseria gonorrhoeae or Chlamydia trachomatis comprising N-(2-aminoethyl)glycine units in amide linkage with the glycine nitrogen connected to naturally occurring nucleobases or non-naturally occurring nucleobases by a methylene carbonyl linker and said probes capable of hybridizing to 16S or 23S rRNA or rDNA of Neisseria gonorrhoeae or Chlamydia trachomatis are described. PNA is a very stable molecule with very high affinity for nucleic acid allowing a PNA probe to be shorter than conventional nucleic acid probes.

Chlamydia major outer membrane protein

Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a β-galactosidase promoter and terminator is provided. Recombinant phage λgt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

Chlamydia antigens

Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

Omv vaccines

The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the Tol-Pal complex (TolR, TolA, TolB, Pal and/or TolQ) and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.

Chlamydia vaccine

Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.

Methods and compositions for attenuated chlamydia as vaccine and vector

The present invention provides Chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

Vaccines against chlamydial infection

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

Omv vaccines

The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the Tol-Pal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.

Compounds and methods for treatment and diagnosis of chlamydial infection

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

Multi-epitope antigen, preparation method thereof and application of multi-epitope antigen in preparation of medicine for preventing and treating chlamydia psittaci infection

本发明涉及免疫学技术领域，尤其涉及多表位抗原及其制备方法与在制备防治鹦鹉热衣原体感染的药物中的应用。本发明提供了SEQ ID NO:1所示氨基酸序列的多表位抗原、包括该抗原的融合多肽及该融合多肽的用途。该抗原分子量小，制备简单，免疫原性与大分子蛋白相当。实验表明，该抗原能够诱导体液和Th1细胞免疫反应产生，产生具有显著意义的特异性抗体以及γ干扰素、白介素2。疫苗接种能显著降低感染小鼠肺组织的衣原体载量以及炎症侵润程度，并显著降低炎性因子IFN‑γ和IL‑6水平。此外，从接种疫苗的小鼠身上获得的CD4+T细胞，经过继转移后显著降低了感染小鼠肺组织的衣原体载量，表明其在细胞免疫应答中具有重要意义。

Compositions capable of facilitating penetration across a biological barrier

This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

i(Chlanydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

本发明涉及编码被分泌的或者是特异性的或者与代谢、复制过程或者毒力有关的肺炎衣原体多肽例如细胞被膜多肽的基因组序列和核苷酸序列，由所述序列编码的多肽，以及含所述序列的载体和用这些载体转换的动物或细胞。本发明还涉及用于控制微生物生长的肺炎衣原体的转录基因产物，例如反义和核酶分子。本发明还涉及检测这些核酸或多肽的方法以及用于诊断肺炎衣原体感染的试剂盒。本发明还涉及筛选能够调节细菌感染之化合物的方法以及用所述核苷酸序列或所述多肽生物合成或者生物降解所研究分子的方法。最后，本发明还包括用于预防和/或治疗细菌，特别是肺炎衣原体感染的药物，特别是疫苗和组合物。

Chlamydia antigens and corresponding DNA fragments and uses thereof

The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia , specifically C. pneumoniae . The vaccine and method employ an OMP (outer membrane protein) of a strain of Chlamydia pneumoniae . Modifications are possible within the scope of this invention.

Method for delivery of substances to intracellular microorganisms

The present invention concerns a method of delivering substances to obligate intracellular microorganisms. Further, the invention concerns a method of treatment of infections of intracellular microorganisms. Further, the invention concerns substances suitable for treatment of infections of intracellular microorganisms. In addition, the invention concerns stable transformants of obligate intracellular microorganisms.

Chlamydia trachomatis antigen for vaccine and diagnostic use

【課題】クラミジア科の細菌が原因である感染の予防、治療または診断に用いる薬学的組成物の提供。 【解決手段】クラミジア・トラコマチスに感染している個体の特異的な抗体によって認識されるか、または同一の個体からＴ細胞を誘発し、γインターフェロンを分泌させることができるクラミジア・トラコマチスの抗原。Ｔ細胞反応性抗原は、全細胞の溶菌液に存在し、ＳＤＳ−ＰＡＧＥにより測定すると、見かけ分子量が５〜１２、１６〜２０、２５〜３５および５８〜７４ｋＤａである。抗原を含有するワクチンおよび診断用組成物。 【選択図】図１

Chlamydia antigens and corresponding dna fragments and uses thereof

Chlamydia antigens and corresponding DNA fragments and uses thereof

The present invention provides a method fo nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding an ATP/ADP translocase of a strain of Chlamydia pneumoniae and a promoter to effect expression of the ATP/ADP translocase gene in the host. Modifications are possible within the scope of this invention.

Chlamydia major outer membrane protein

@ Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a β-galactosidase promoter and terminator is provided. Recombinant phage λgt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, on January 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on December 31, 1985, and granted accession no 40217.

Dna immunization against chlamydia infection

Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP fragment in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

Chlamydia antigens and corresponding DNA fragments and uses thereof

(57)【要約】 本発明は、Chlamydia pneumoniae株の９８ＫＤａ外膜タンパク質をコードするヌクレオチド配列と宿主において９８ＫＤａ外膜タンパク質遺伝子を発現させるプロモーターとを含むベクターを用いて、Chlamydia、特にC.pneumoniae株の感染により引き起こされる疾患に対して、ヒトを含む宿主をＤＮＡを含む核酸により免疫する方法を提供する。本発明の範囲内において改変が可能である。

Target gene disruption method and immunogenic composition

偏性細胞内細菌における特異的遺伝子機能の破壊及びその後のその活性の復元は、複製するための宿主細胞内でのそれらの絶対的必要性に起因して、依然として極めて困難である。本発明では、リケッチア病原体であるエーリキア・シャフェンシスの２つの遺伝子を不活性化し、その後に、その２つの遺伝子のうちの一方を復元するために、標的アレル交換変異体を作製した。本方法は、エーリキア・カニス及びアナプラズマ・ファゴサイトフィルムにも成功裏に用いられた。作製された変異病原体は、リケッチア病原体による感染の発生率または重症度を低減させるための免疫原性組成物において有用である。【選択図】図１

Compounds and methods for treatment and diagnostics of chlamydia infection

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: compounds, included into one of compositions represent polypeptides, which contain at least immunogenic fragment of protein CT858 or protein CT089 Chlamydia trachomatis with specific amino acid sequence, or polynucleotides, coding immunogenic fragments of said proteins. Compounds, included into other composition, represent fused polypeptides, which contain immunogenic fragment of protein CT858 or CT089 and fusion partner, selected from immunologic fusion partners, expression amplifiers, affine markers and unrelated known proteins of Chlamydia trachomatis. Said compositions can be used for stimulation of specific T-cell response to Chlamydia trachomatis, for inhibition of infection development and for treatment of infection induced by Chlamydia trachomatis, ensuring high level of immune response and therapeutic effect. ^ EFFECT: described are compositions based on compounds for prevention and treatment of Chlamydia infection. ^ 11 cl, 16 dwg, 7 tbl, 13 ex

Chlamydia antigens and corresponding dna fragments and uses thereof

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an mip protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the mip gene in the host. Modifications are possible within the scope of this invention.

Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

(chlamydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Chlamydia protein, gene sequence and uses thereof

Chlamydial protease-like activity factor responsible for degradation of host transcription factor

Microbial pathogens have been selected for the capacity to evade or manipulate host responses in order to survive after infection. Chlamydia, an obligate intracellular pathogen and the causative agent for many human diseases, can escape T lymphocyte immune recognition by degrading host transcription factors required for major histocompatibility complex (MHC) antigen expression. We have now identified a chlamydial protease-like activity factor (CPAF) that is secreted into the host cell cytosol and that is both necessary and sufficient for the degradation of host transcription factors RFX5 and upstream stimulation factor 1 (USF-1). The CPAF gene is highly conserved among chlamydial strains, but has no significant overall homology with other known genes. Thus, CPAF represents a unique secreted protein produced by an obligate intracellular bacterial pathogen to interfere with effective host adaptive immunity.